Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
BURLINGTON, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. Eastern Time at the Westin Grand Central Hotel in New York City.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable, non-opioid drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead product candidate, Zilretta™, has been designed to provide improved analgesic therapy for the five million patients who receive intra-articular (IA) injections for osteoarthritis (OA) of the knee annually. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an IA, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
CONTACTS: Investor Relations Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Relations Contact Mariann Caprino TogoRun 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
